I agree that this site is using cookies. You can find further informations here.
X
El Ghali, Amer
36  results:
Search for persons X
?
1

Cefiderocol: early clinical experience for multi-drug resis..:

El Ghali, Amer ; Kunz Coyne, Ashlan J. ; Lucas, Kristen...
Microbiology Spectrum.  12 (2024)  2 - p. , 2024
Link: https://doi.org/10.1128/..
 
?
2

High-dose Cefepime vs Carbapenems for Bacteremia Caused by ..:

Kunz Coyne, Ashlan J ; El Ghali, Amer ; Lucas, Kristen...
Open Forum Infectious Diseases.  10 (2023)  3 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
3

Optimization of Phage-Antibiotic Combinations against Staph..:

Kebriaei, Razieh ; Lehman, Susan M. ; Shah, Rahi M....
Microbiology Spectrum.  11 (2023)  3 - p. , 2023
Link: https://doi.org/10.1128/..
 
?
4

Risk Factors for Carbapenem-ResistantEnterobacteralesClinic..:

Rebold, Nicholas ; Lagnf, Abdalhamid M. ; Alosaimy, Sara...
Microbiology Spectrum.  11 (2023)  1 - p. , 2023
Link: https://doi.org/10.1128/..
 
?
5

2118. Comparative Analysis of Cefiderocol Mono- and Combina..:

Ghali, Amer El ; Kunz-coyne, Ashlan ; Lucas, Kristen...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
6

Long-term evaluation of clinical success and safety of omad..:

El Ghali, Amer ; Morrisette, Taylor ; Alosaimy, Sara...
Antimicrobial Agents and Chemotherapy.  67 (2023)  10 - p. , 2023
Link: https://doi.org/10.1128/..
 
?
7

1422. A Multi-Center Evaluation of Omadacycline for Multi-D..:

Ghali, Amer El ; Ghali, Amer El ; Allosaimy, Sara...
Open Forum Infectious Diseases.  9 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
8

1691. Bacteriophage and Protein Synthesis Pathway Inhibitor..:

Kunz Coyne, Ashlan J ; Bhutani, Natasha ; Holger, Dana...
Open Forum Infectious Diseases.  9 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
9

679. Traditional vs. Alternative Agents in Patients with Lo..:

Holger, Dana J ; Lagnf, Abdalhamid M ; Belza, Ana Christine...
Open Forum Infectious Diseases.  9 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
10

633. Eravacycline Use in Immunocompromised Patients: Multic..:

Kunz Coyne, Ashlan J ; Allosaimy, Sara ; Molina, Kyle C...
Open Forum Infectious Diseases.  9 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
11

Impact of Ceftolozane–Tazobactam vs. Best Alternative Thera..:

Holger, Dana J. ; Rebold, Nicholas S. ; Alosaimy, Sara...
Infectious Diseases and Therapy.  11 (2022)  5 - p. 1965-1980 , 2022
Link: https://doi.org/10.1007/..
 
?
12

Phage Cocktails with Daptomycin and Ampicillin Eradicates B..:

Kunz Coyne, Ashlan ; Stamper, Kyle ; Kebriaei, Razieh...
Antibiotics.  11 (2022)  9 - p. 1175 , 2022
Link: https://doi.org/10.3390/..
 
?
13

Therapeutic Strategies for Emerging Multidrug-Resistant Pse..:

Kunz Coyne, Ashlan J. ; El Ghali, Amer ; Holger, Dana..
Infectious Diseases and Therapy.  11 (2022)  2 - p. 661-682 , 2022
Link: https://doi.org/10.1007/..
 
?
14

1270. Early Real-world Evidence in the Use of Eravacycline ..:

Carr, Amy ; El Ghali, Amer ; Kaur, Parminder..
Open Forum Infectious Diseases.  7 (2020)  Supplement_1 - p. S651-S652 , 2020
Link: https://doi.org/10.1093/..
 
?
15

High-dose Cefepime vs Carbapenems for Bacteremia Caused by ..:

Kunz Coyne, Ashlan J ; El Ghali, Amer ; Lucas, Kristen...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034593/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-15